Home
Services
Digital
Technology
RFP Builder
News
About
Careers
Giving
Services
Digital
Technology
RFP Builder
Careers
About us
Get in touch
Home
Services
Digital
Technology
RFP Builder
News
About
Careers
Giving
Services
Digital
Technology
RFP Builder
Careers
About us
Get in touch

Respecting the technical, delivering the practical

Our expert team will be at ISPOR Annual Montreal, Canada in May 2025. ISPOR is the leading global conference for Health Economics and Outcomes Research and the best place to discuss and disseminate the latest trends in healthcare.
Find out more
Welcome to price transparency with RFP Builder
By matching project requirements, the RFP Builder provides custom quotes, ensuring a perfect alignment with project needs without even having to speak to anyone at FIECON!
Explore pricing
Everything you always wanted to know about JCA
What is JCA?  Is my product eligible? The Joint Clinical Assessment (JCA) for oncology, haematology, and ATMPs will be eligible for assessment from January 12th, 2025 with two significant updates this month.
Read more
FIECON's Social Responsibility report
Understand our initiatives, milestones, and the substantial progress we have made towards our 2030 goals, including becoming B Corporation® certified and a certified Great Place To Work®.
Read more

Key services

We are committed to to supporting the commercialisation of products that make a difference in people’s lives. We work across a product’s lifecycle, to support pharma, med tech and biotech companies around the world.
Outcomes Research
Our team provide unequalled accuracy and quality whilst delivering all aspects of systematic reviews, meta-analyses and patient-level data analyses.
Economic Modelling
We develop a range of robust health economic models that meet the commercial needs of our clients from simple Markov models to complex discrete event simulations.
Health Technology Assessment
We have extensive experience delivering successful HTA submissions in the UK and across the globe.
Value Communication
At FIECON, we understand the value of clear and concise writing, underpinned by robust evidence. We effectively communicate the value of our clients' products in a clear, logical and impactful manner; from global value dossiers to external scientific publications.
Pricing & Reimbursement
We partner with our clients to develop strategies for global pricing and reimbursement, harnessing our extensive KOL and payer network.
Real World Evidence
Our team offers comprehensive real world evidence (RWE) services, including the development of tailored RWE strategies and conducting evidence gap analyses.

Digital Innovation for Strategic Success

At FIECON, we use digital solutions, advanced technology, and AI to enhance the quality of our health economics and market access strategies. By automating processes and improving data analysis, we deliver precise, tailored solutions that optimize product commercialization and ensure strategic success​​.

Technology

We leverage bespoke technology to enhance the accuracy and efficiency of our economic modelling and statistical analysis. Tailored to our clients' needs, ensuring our analyses  are high quality and resonate with stakeholders and drive successful outcomes.

Digital solutions

Our expert UX (user experience) and design team excel in crafting validated, impactful communication tools tailored to support negotiations with local and regional decision-makers. We specialise in facilitating internal and external value communications, ensuring messages resonates with key stakeholders.

Private AI Platform

Our tailored, private LLM platform enables us to use AI as a human copilot, enhancing decision-making while ensuring data privacy in a secure environment. This approach streamlines processes and delivers precise, data-driven solutions, allowing our experts to focus on delivering high-quality strategic advice.
FIECON exceeds my expectations by genuinely trying to achieve the best outcomes for our company. Their flexibility to adapt to unexpected changes and apply technical rigour, while respecting the commercial focus of the company is unparalleled.  We see FIECON as part of our extended team.”
Senior Market Access Manager, Mid-sized Pharma
It was brilliantly smart and very well explained. It seems obvious now but that is what genius is, making complex things appear simple.”
Associate Director, Mid-sized Pharma
FIECON are my go to trusted partner. The team deliver high-quality work to timeline, every time. But more than this, FIECON has worked as part of our team, working towards achieving the best possible outcome by providing high level strategic input and challenge during our discussions.”
Market Access Director, Small Biotech
FIECON’s highly skilled expert team helped us to successfully tackle a number of tough pricing and access challenges. Apart from their flawless technical expertise, we have a reliable thought partner to pressure test new ideas and strategies that have a broader relevance than purely health economic aspects.”
Disease Area Director, Big Pharma
The pricing and market access research was a high quality work project, which included detailed information to define the overall and country strategy while the gap analysis was instrumental in the next steps preparation. ”
Executive Director, Biotech
FIECON’s strategic approach to problem solving is a breath of fresh air. We highly value their HTA knowledge and expertise, and they consistently deliver the best solution for us.”
Value Demonstration & Access Lead, Big Pharma
It is a pleasure to work with FIECON. The team are passionate about what they do and it really shows in their high-quality, creative solutions. Working with FIECON gives your projects the highest chance of success.”
Senior Vice President, Small Biotech
FIECON’s team is highly experienced, commercially focused, responsive and flexible. A particular strength I highlight is that FIECON’s team becomes a true partner with all company functions that they interact with. ”
Executive Director, Biotech

Keeping up to date

NICE published surrogate endpoints guidance: insights from Dawn
On January 20th, NICE published a new report offering best practice recommendations for using surrogate endpoints in health economic models. In this interview, Dawn Lee, a member of FIECON's Strategic Council who participated in the meetings to develop the guidance and reviewed the draft, shares her insights as a NICE committee member.
Read more
Starting a career to drive positive change
Grace Newman, a recent graduate who joined FIECON in September 2024, shares her journey and experiences as an Associate, offering insights for recent graduates interested in joining the team.
Read more
Stories over statistics: Richard and Caroline talk about Rare Disease
As Rare Disease Day approaches, Caroline, Associate Director at FIECON, and Richard, Head of Client Partnerships at FIECON, discuss the crucial role of HEOR in improving the lives of rare disease patients, and their families and care givers.
Read more

Get in touch

Get a completely free, no-obligation opportunity to discuss your needs and see how we can boost your business.
  • Brainstorm solutions to key challenges with experienced team
  • Validate your strategy and value evidence
  • Learn more about FIECON’s products and key areas of expertise and discuss opportunities for collaboration

Your contact details

I would like to
By submitting this form, you confirm that you agree to our website terms of use

Thank you!

We received your details. Someone from our team will contact you soon.
Oops!
Something went wrong while submitting the form.
About us
Services
Get in touch
Privacy Policy
Cookie Policy
Consent Preferences
© Fiecon 2024